ENHANCEMENT OF STABILITY, RELEASE AND IN VITRO DIGESTIBILITY OF MULBERRY STEM EXTRACT USING MICROEMULSIONS
Objective: This study was aimed to develop oral microemulsions and to evaluate their ability to enhance stability, release and intestinal digestion of mulberry stem extract (MSE).
Methods: The pseudoternary phase diagrams were constructed using caprylic/capric triglyceride (oil), PEG-8 caprylic/capric glycerides (S), polyglyceryl-3 diisostearate (CoS) and an aqueous phase. The effects of S/CoS (Km) ratio and a cosolvent, i.e. polyethene glycol 400 or propylene glycol (PG), were investigated. The optimized formulations were selected and incorporated with MSE. Then, they were then subjected to stability, release and lipolysis studies. The control solution consisted of 50% PG and 50% water.
Results: The formation and characteristics of the microemulsions were influenced by Km and cosolvents. The two optimized formulations (F3 and F4) consisted of 10% oil, 70% S/CoS mixture and 20% aqueous phase were chosen. The Km ratios of F3 and F4 were 4:1 and 3:1. The aqueous phase of F3 and F4 was water and water mixed with PG, respectively. These formulations could improve the stability of MSE better than the control solution. The accumulated release of MSE from F3, F4 and the control solution reached 100% while that of unformulated crude extract reached only 70% after 6 h. The lipolysis study showed that MSE incorporated in both F3 and F4 was digested more than double the percentage compared to that of MSE incorporated in the control solution.
Conclusion: MSE was successfully developed in microemulsions. They are shown to be promising vehicles for oral delivery of MSE. Further animal trials are suggested.
2. Chung KO, Kim BY, Lee MH, Kim YR, Chung HY, Park JH, et al. In vitro and in vivo anti-inflammatory effect of oxyresveratrol from Morus alba L. J Pharm Pharmacol 2003;55:1695-700.
3. Bown D. Encyclopedia of herbs and their uses. London: Dorling Kindersley; 1995.
4. Chan E WC, Lye PY, Wong SK. Phytochemistry, Pharmacology and clinical trials of Morus alba. Chin J Nat Med 2016;14:17-30.
5. Lemus I, Garcia R, Delvillar E, Knop G. Hypoglycaemic activity of four plants used in Chilean popular medicine. Phytother Res 1999;13:91â€“4.
6. Metwally FM, Ahmed HH, Rashad H, Zaazaa AM. Insights into the role of Morus alba in reversing obesity-associated steatosis and related metabolic disorder in rats. Asian J Pharm Clin Res 2016;9 Suppl 2:231-8.
7. Soonthornsit N, Pitaksutheepong C, Hemstapat W, Utaisincharoen P, Pitaksuteepong T. In vitro anti-inflammation activity of Morus alba L. stem extract in LPS-stimulated RAW 264.7 cells. Evid Based Complement Alternat Med 2017. Doi:10.1155/2017/3928956.
8. Pham PP, Morales NP, Pitaksuteepong T, Hemstapat W. Antioxidant activity of mulberry stem extract: a potential used as a supplement for oxidative stress-related diseases. Songklanakarin J. Sci. Technol; 2017. p. 7-31.
9. Khunakornvichaya A, Lekmeechai S, Pham PP, Himakoun W, Pitaksuteepong T, Morales NP, Hemstapat W. Morus alba L. stem extract attenuates pain and articular cartilage damage in the anterior cruciate ligament transection-induced rat model of osteoarthritis. Pharmacology 2016;98:209-16.
10. Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed 2013;3:253-66.
11. Munin A, Edwards-Levy F. Encapsulation of natural polyphenolic compounds; a review. Pharmaceutics 2011;3:793-829.
12. Yhirayha C. Formulation and skin penetration study of lyotropic liquid crystal incorporating mulberry stem (Morus alba L.) extract. Master thesis. M. Sc. Naresuan University, Phitsanulok; 2013.
13. Kaur H, Kaur G. A critical appraisal of solubility enhancement techniques of polyphenols. J Pharm 2014. http://dx.doi.org/10.1155/2014/180845
14. Eccleston GM. Microemulsions. In: Swarbrick J, Boylan J. editors. Encyclopedia of Pharmaceutical Technology. Marcel Dekker, New York; 1992. p. 375-421.
15. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Delivery Rev 2002;54 Suppl 1:S77-S98.
16. Liu DZ, Lecluyse EL, Thakker DR. Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J Pharm Sci 1999;88,1161-8.
17. Paul BK, Moulik SP. Uses and applications of microemulsions. Curr Sci 2001;80,990â€“1001.
18. Gundogdu E, Alvarez IG, Karasulu E. Improvement of the effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies. Int J Nanomed 2001;6:1631â€“40.
19. Zhong GG. Thermally Reversible microemulsion for oral delivery of poorly water-soluble drugs. In: Najjar R. editor. Microemulsions-An Introduction to properties and applications. Publisher: InTech; 2012. p. 135-50.
20. Noi-ang T, Charoensin A, Warangkanagool A, Soonthornsit N, Pitaksuteepong T. Development of oral microemulsions of Morus alba extract for osteoarthritis. Adv Mat Res 2015; 1060:41-4.
21. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Controlled Release 2009;140:86-94.
22. Swenson ES, Curatolo WJ. Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Delivery Rev 1992;8:39-92.
23. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterization and transdermal drug delivery potential of microemulsions. J Controlled Release 2000;69:421â€“33.
24. Rama Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, et al. Enhanced intestinal absorption of vancomycin with labrasol and d-ï¡-tocopheryl PEG 1000 Succinate in rats. Int J Pharm 2003a; 250:181â€“90.
25. Rama Prasad YV, Eaimtrakarn S, Ishida M, Kusawake Y, Tawa R, Yoshikawa Y, et al. Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs. Int J Pharm 2003b;268:13â€“21.
26. Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K. Enhancing mechanism of labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm 2006;64:82â€“91.
27. Lawrence MJ, Rees GD. Microemulsion-based on as novel drug delivery systems. Adv Drug Delivery Rev 2000;45:89-121.
28. Freire AC, Basit AW. Dissolution testing of solid dosage forms. In: Aulton ME, Taylor KMG. editors. Aultonâ€™s pharmaceutics: the design and manufacture of medicines. 4th ed. London: Elsevier; 2013. p. 611-22.
29. Larsen AT, Sassene P, Mullertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant-based drug delivery systems. Int J Pharm 2011;417:245-55.
30. Xiao L, Yi T, Liu Y, Zhou H. The in vitro lipolysis of lipid-based drug delivery systems: a newly identified relationship between drug release and lipid crystalline phase. Biomed Res Int 2016. http://dx.doi.org/10.1155/2016/2364317
31. Gao ZG, Choi HG, Shin HJ, Park KM, Lim SJ, Hwang KJ, et al. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int J Pharm 1998;161:75-86.
32. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems an overview. Acta Pharm Sin B 2013;3:361-72.